NeoStem expands into cardiovascular space with $18 million Amorcyte buy
This article was originally published in Scrip
Executive Summary
Stem cell specialist NeoStem has agreed to purchase Amorcyte, a cardiovascular stem cell therapy developer, a move which will give it access to the cardiovascular therapy market. Amorcyte's lead product, AMR-001, is about to start a Phase II trial in acute myocardial infarction (AMI).